Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline

S Lutz, L Berk, E Chang, E Chow, C Hahn… - International Journal of …, 2011 - Elsevier
PURPOSE: To present guidance for patients and physicians regarding the use of
radiotherapy in the treatment of bone metastases according to current published evidence …

Guidelines for supportive care in multiple myeloma 2011

JA Snowden, SH Ahmedzai, J Ashcroft… - British journal of …, 2011 - Wiley Online Library
Supportive care plays an increasingly important role in the modern management of multiple
myeloma. While modern treatments have significantly prolonged overall and progression …

Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial

S Siva, M Bressel, DG Murphy, M Shaw, S Chander… - European urology, 2018 - Elsevier
Background Stereotactic ablative body radiotherapy (SABR) is an emerging treatment option
for oligometastatic prostate cancer. However, limited prospective evidence is available …

Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases

E Chow, P Hoskin, G Mitera, L Zeng, S Lutz… - International Journal of …, 2012 - Elsevier
PURPOSE: To update the international consensus on palliative radiotherapy endpoints for
future clinical trials in bone metastases by surveying international experts regarding …

Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled …

E Chow, RM Meyer, K Ding, A Nabid, P Chabot… - The Lancet …, 2015 - thelancet.com
Background Pain flare occurs after palliative radiotherapy, and dexamethasone has shown
potential for prevention of such flare. We aimed to compare the efficacy of dexamethasone …

[HTML][HTML] Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha …

MJ van der Doelen, N Mehra, IM van Oort… - … Oncology: Seminars and …, 2021 - Elsevier
Introduction Targeted alpha-radiation therapy (TAT) with 225 Ac-labeled prostate-specific
membrane antigen (PSMA) ligands is a promising novel treatment option for metastatic …

[HTML][HTML] A randomised trial of 4-versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate …

M Clemons, M Ong, C Stober, S Ernst, C Booth… - European Journal of …, 2021 - Elsevier
Background Optimal dosing of bone-targeted agents (BTAs), in patients with bone
metastases remains an important clinical question. This trial compared 4-weekly versus 12 …

Comparison of minimally invasive surgery with standard open surgery for vertebral thoracic metastases causing acute myelopathy in patients with short-or mid-term …

M Miscusi, FM Polli, S Forcato, L Ricciardi… - … of Neurosurgery: Spine, 2015 - thejns.org
OBJECT Spinal metastasis is common in patients with cancer. About 70% of symptomatic
lesions are found in the thoracic region of the spine, and cord compression presents as the …

The incidence and clinical impact of bone metastases in non-small cell lung cancer

M Kuchuk, I Kuchuk, E Sabri, B Hutton, M Clemons… - Lung Cancer, 2015 - Elsevier
Introduction Non-small cell lung cancer (NSCLC) is the leading global cause of cancer
death. While bone metastases (BM) commonly cause morbidity, bone-targeted agent (BTA) …

A smart IoT platform for oncology patient diagnosis based on ai: Towards the human digital twin

D Mourtzis, J Angelopoulos, N Panopoulos… - Procedia CIRP, 2021 - Elsevier
Human cancer is a multifaceted decease. Throughout the years several techniques and
technologies have been proposed for the diagnosis and treatment of such deceases …